Phoenix Biotech Acquisition Accounts Payable

Phoenix Biotech Acquisition (PBAX) currently reports a accounts payable of $7.7M as of March 2026. That compares with $6.4M in the prior-year period — up 20.5% year over year. Use the charts on this page to explore Phoenix Biotech Acquisition's accounts payable history and peer comparisons.

Phoenix Biotech Acquisition's accounts payable increased from $6.4M to $7.7M — a 20.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Phoenix Biotech Acquisition reported $7.7M in accounts payable as of March 2026. That compares with $6.4M in the prior-year period — up 20.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $7.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Phoenix Biotech Acquisition, and consider following PBAX for alerts when major investors trade the stock.